GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Net Income

Giant Biogene Holding Co (HKSE:02367) Net Income : HK$1,588 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Giant Biogene Holding Co's Net Income for the six months ended in Dec. 2023 was HK$858 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,588 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Giant Biogene Holding Co's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.89.


Giant Biogene Holding Co Net Income Historical Data

The historical data trend for Giant Biogene Holding Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Net Income Chart

Giant Biogene Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
614.53 979.70 1,014.02 1,118.98 1,587.90

Giant Biogene Holding Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Get a 7-Day Free Trial - 512.54 630.70 729.49 858.41

Giant Biogene Holding Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Giant Biogene Holding Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=1908.742+-324.729+0+3.884
=1,588

Giant Biogene Holding Co's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=1060.425+-204.894+0+2.8810000000001
=858

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,588 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Giant Biogene Holding Co  (HKSE:02367) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Giant Biogene Holding Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Giant Biogene Holding Co Net Income Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Giant Biogene Holding Co (HKSE:02367) Business Description

Traded in Other Exchanges
N/A
Address
No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Executives
Refulgence Holding Limited 2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd 2101 Beneficial owner
Fan Daidi 2201 Interest of corporation controlled by you
Yan Jianya 2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Yan Jianya 2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited 2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines